Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 417180.0%.

  • Altimmune's EBIT Margin rose 781600000.0% to 417180.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 452310.0%, marking a year-over-year decrease of 2370619200.0%. This contributed to the annual value of 515860.0% for FY2024, which is 4933414600.0% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's EBIT Margin is 417180.0%, which was up 781600000.0% from 458440.0% recorded in Q2 2025.
  • Over the past 5 years, Altimmune's EBIT Margin peaked at 731.92% during Q4 2021, and registered a low of 1237600.0% during Q3 2022.
  • In the last 5 years, Altimmune's EBIT Margin had a median value of 254937.5% in 2022 and averaged 292639.73%.
  • As far as peak fluctuations go, Altimmune's EBIT Margin plummeted by 2000000000bps in 2022, and later soared by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows Altimmune's EBIT Margin stood at 731.92% in 2021, then plummeted by -12036bps to 88823.08% in 2022, then fell by -2bps to 90872.97% in 2023, then plummeted by -447bps to 497320.0% in 2024, then grew by 16bps to 417180.0% in 2025.
  • Its EBIT Margin stands at 417180.0% for Q3 2025, versus 458440.0% for Q2 2025 and 436300.0% for Q1 2025.